Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Summary
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
Official title: A Phase 2 Study of DZD8586 Combination Therapy in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
66
Start Date
2025-09-22
Completion Date
2030-01
Last Updated
2025-12-24
Healthy Volunteers
No
Interventions
DZD8586
DZD8586 will be taken orally once daily on days 1-28 of each cycle.
Venetoclax
Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day 1.
Locations (15)
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Yichang Central People's Hospital
Yichang, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First People's Hospital of Changzhou
Changzhou, Jiangsu, China
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China